Gilead's Biktarvy Patent Extended to 2036
Gilead Sciences settled lawsuits with generic manufacturers, securing market exclusivity for Biktarvy until April 2036.
Already have an account? Sign in.
Gilead Sciences settled lawsuits with generic manufacturers, securing market exclusivity for Biktarvy until April 2036.
Luminar (LAZR) reports 20% revenue increase in Q3 2025 but faces serious cash crunch with only $74M remaining. Company exploring sale options and restructuring debt.
Novo Nordisk and Eli Lilly reject Mangoceuticals' false partnership claims regarding weight-loss drugs.
Auto parts supplier LKQ Corp is planning to sell its Keystone specialty division for around $1 billion as investors pressure the company to maximize shareholder value and restructure operations.